Nattokinase
Nattokinase (Subtilisin NAT)
Also known as: Subtilisin NAT, NSK-SD (standardized branded extract)
A fibrinolytic enzyme from Bacillus subtilis natto fermentation with a genuinely large human trial record for a supplement, including randomized blood pressure trials and a 3 year placebo-controlled outcome study, but no hard cardiovascular endpoint trial and a carotid-plaque result that is widely cited despite not being placebo-controlled.
Overview
Nattokinase is a 275 amino acid serine protease of the subtilisin family, produced when the bacterium Bacillus subtilis var. natto ferments boiled soybeans into natto, a food eaten in Japan for centuries. It was first isolated and named by Hiroyuki Sumi in 1987, who described a strong fibrinolytic (clot-dissolving) activity in natto extract. Unlike most compounds in this database, nattokinase already has a real body of human trial data: more than 15 published human studies, several of them randomized and placebo-controlled, including one that ran for a median of 3 years. Blood pressure is the outcome with the most consistent support. A 2023 meta-analysis pooling 6 randomized trials (546 participants) found nattokinase lowered systolic blood pressure by 3.45 mmHg and diastolic by 2.32 mmHg versus placebo, and the largest single trial in this area found a similar effect in a North American population, not only the Japanese, Chinese and Taiwanese cohorts most of the literature comes from.
The carotid-artery claim that circulates most widely about nattokinase, that it shrinks arterial plaque, rests on thinner ground than the blood pressure claim. The most-cited positive result is a 2017 Chinese trial that randomized 82 patients to nattokinase or simvastatin and found a larger drop in plaque size and carotid intima-media thickness with nattokinase, but it had no placebo arm and was not blinded. A larger 2022 report of 1,062 patients found similar imaging improvements, but it was retrospective, uncontrolled, unblinded, and five of its ten authors worked for the company that manufactures the nattokinase product tested. Against both of those sits the best-designed trial nattokinase has: a placebo-controlled, double-blind, USC-run trial of 265 healthy older adults that dosed nattokinase for a median of 3 years and found no significant effect on carotid intima-media thickness, arterial stiffness, blood pressure, or any laboratory marker measured. Pooled lipid data from randomized trials point the same cautious direction: the 2023 meta-analysis found no lipid benefit from nattokinase alone, and total cholesterol actually ran slightly higher than placebo across the pooled trials.
No trial of any size has tested whether nattokinase reduces heart attacks, strokes, or deaths. Every positive human result to date is a blood pressure number, a coagulation marker, or a carotid ultrasound measurement, not a hard clinical outcome.
Mechanism of action
Nattokinase acts through several routes rather than one. It directly hydrolyzes fibrin and fibrinogen; it converts endogenous prourokinase to active urokinase; it degrades plasminogen activator inhibitor-1 (PAI-1), the protein that normally restrains the body's own clot-dissolving system; and cell-culture work found that heat-inactivated Bacillus subtilis natto culture and marketed nattokinase both stimulate tissue plasminogen activator (tPA) release from human vascular endothelial cells and HeLa cells, raising tPA activity several-fold over control. Together these give nattokinase both a direct fibrinolytic action and an indirect one that amplifies the body's own clot-breakdown machinery. A single-dose randomized crossover trial in 12 healthy men showed this translates into measurable, if modest, changes in human coagulation markers within hours: elevated D-dimer and fibrin degradation products, reduced factor VIII activity, higher antithrombin, and a prolonged activated partial thromboplastin time, all of which stayed within the normal laboratory range. X-ray crystallography shows nattokinase is structurally almost identical to subtilisin E, differing at essentially one residue, and pharmacokinetic work in 11 healthy adults found the intact enzyme is directly measurable in human serum, peaking roughly 13 hours after a single oral dose, which was the first direct evidence it survives digestion and reaches the bloodstream in an active form.
Human evidence
Nattokinase has more human data behind it than almost anything else in this database: over 15 published human studies, several randomized and placebo-controlled, plus a 3-year placebo-controlled trial that is the largest and longest ever run on it. Blood pressure is the best-supported outcome. Fibrinolytic and coagulation markers move in a consistent, mechanistically plausible direction across several small trials. Carotid imaging is where the record splits hardest: the most-cited positive study was not placebo-controlled, and the one rigorous long-term trial found nothing at all.
- Blood pressure, meta-analysis (Li et al. 2023): pooling 6 RCTs and 546 participants, nattokinase lowered systolic blood pressure by 3.45 mmHg and diastolic by 2.32 mmHg versus placebo (both p<0.00001). The individual trial behind much of this, a Korean RCT in 86 people with pre-hypertension or stage 1 hypertension, found -5.55 mmHg systolic and -2.84 mmHg diastolic after 8 weeks at 2,000 FU/day. A separate North American RCT in 79 hypertensive adults, industry-sponsored, found a similar diastolic effect concentrated in men.
- Coagulation and fibrinolysis markers, several small trials: a 45-person open-label trial found fibrinogen, factor VII and factor VIII all fell significantly over 2 months at 4,000 FU/day, with no control arm. A 12-person double-blind placebo-controlled crossover RCT found a single 2,000 FU dose measurably raised D-dimer and fibrin degradation products and prolonged clotting time within hours, changes that stayed inside the normal range and are consistent with the proposed mechanism rather than evidence of clinical benefit by themselves.
- Carotid atherosclerosis, the most-cited and most contested finding: an 82-patient Chinese trial randomized nattokinase against simvastatin (no placebo arm, not blinded) and found a larger fall in carotid plaque size and intima-media thickness with nattokinase over 26 weeks. A larger, 1,062-patient retrospective review from the same country found similar imaging improvements at a high dose and none at a threefold lower dose, but it was uncontrolled, unblinded, and half its authors worked for the nattokinase manufacturer.
- Carotid atherosclerosis, the contradicting result: the Nattokinase Atherothrombotic Prevention Study, a placebo-controlled, double-blind RCT run at USC in 265 healthy older adults for a median of 3 years, found no significant effect on carotid intima-media thickness, arterial stiffness, blood pressure, or any laboratory marker tested. This is the best-designed and longest nattokinase trial that exists, and it is null.
- Lipids, meta-analysis versus individual trials: the pooled RCT data found no lipid benefit from nattokinase alone, with total cholesterol running slightly higher than placebo. Individual trials that report large lipid improvements typically combine nattokinase with red yeast rice, whose own cholesterol-lowering effect is well established, making it hard to credit nattokinase specifically; one RCT found nattokinase alone produced no significant lipid change against placebo across 6 months while the same product combined with red yeast rice worked from month 1.
- Two documented serious harms: a case report of a 92-year-old woman with atrial fibrillation who died of spontaneous abdominal bleeding while taking over-the-counter nattokinase and no other blood-affecting drug, and a case report of a mechanical heart valve patient who developed a valve thrombus after substituting nattokinase for warfarin for about a year, requiring repeat valve surgery.
- Currently recruiting: an independent, non-industry, double-blind, placebo-controlled RCT in 48 hypertensive, dyslipidemic adults in Brazil (NCT06183307), with results expected in 2026 or later.
What this does not tell you: No trial of any size has tested whether nattokinase changes the rate of heart attack, stroke, or death; every positive finding is a biomarker or an imaging measurement, not a hard clinical outcome. The single best-designed trial, run over 3 years with a placebo arm, found no effect on anything it measured, including the very imaging measure the most-cited positive studies rely on. Most of the positive carotid and lipid results come from small, unblinded, or uncontrolled studies run at a handful of clinics in China, several with authors employed by the company selling the product tested, which is a pattern that should lower confidence in the size of the effect even where a real signal exists. Fibrinolytic units (FU) are not a pharmacopeial standard, and different manufacturers use different assay methods to arrive at a labeled FU count, so a dose in one brand's capsules is not guaranteed to match the same number in another's.
Reading the research record
Nattokinase is a clean example of a molecule the trial system was never going to fund properly, and it is worth being precise about why. Bacillus subtilis natto fermentation of soybeans is a centuries-old Japanese food process, described in the scientific literature since 1987; nobody can patent the resulting enzyme as a new composition of matter, and no manufacturer could recoup the cost of a large cardiovascular outcome trial, the kind that runs thousands of patients for several years and costs hundreds of millions of dollars, if a dozen other companies could sell the identical fermented soybean extract the day it was approved. That is not a criticism of the compound. It is an accounting fact about who pays for Phase 3 trials and why a molecule that has been eaten for a thousand years still has no outcome data.
The practical consequence shows up directly in how nattokinase is regulated and sold. In the United States it is a dietary supplement under DSHEA, which means a label may carry a structure/function claim, something like supporting healthy circulation, as long as it carries the required disclaimer that FDA has not evaluated the statement, but it may not claim to treat, prevent, or reduce the risk of any disease. FDA has enforced that line against nattokinase specifically: in August 2020 it sent a warning letter to a seller marketing a nattokinase-containing product as able to decrease plaque buildup and help prevent a heart attack or stroke, and it treated those as illegal drug claims regardless of whatever evidence the company thought it had. That is the DSHEA bargain working as designed. A manufacturer who genuinely believed the carotid-plaque literature supported its product still could not legally say so on the label, because structure/function claims and disease claims are different legal categories and the line does not move for good data.
The evidence itself splits along exactly the fault line you would predict from the funding picture. The positive carotid and lipid results mostly come from small clinics in China, unblinded, often uncontrolled, and in the largest of them, authored in part by employees of the company that manufactures the product being tested. The one trial built to the standard a drug would need to clear, placebo-controlled, double-blind, run for years by an academic center with no ties to a nattokinase seller, found nothing. That does not mean the smaller positive studies are wrong; a genuinely real effect can still show up more easily in an open-label single-center study than in a rigorous multi-year trial, and a null result in healthy older adults at low cardiovascular risk does not rule out a benefit in a higher-risk population that has not been tested. But it does mean the confident version of the nattokinase story, that it measurably shrinks arterial plaque, is resting on the weaker half of the evidence rather than the stronger half.
The honest caveat runs in both directions and needs to be stated plainly. The funding argument explains why no outcome trial exists; it does not by itself show that nattokinase would pass one if someone ran it. A biomarker or imaging change is not the same thing as fewer strokes or heart attacks, and nobody knows whether the blood pressure and fibrinolytic effects that are reasonably well established here would translate into fewer cardiovascular events over years of use. That question is, at present, unanswerable, not because the compound has been tested and failed, but because the trial that would answer it has never been run and probably never will be.
Key studies & citations
- In vitro1987
A novel fibrinolytic enzyme (nattokinase) in the vegetable cheese Natto; a typical and popular soybean food in the Japanese diet
The discovery paper. Sumi and colleagues extracted a strong fibrinolytic enzyme from natto, named it nattokinase, and estimated its molecular weight at about 20 kDa, the first published characterisation of the enzyme now studied in human trials.
Experientia - In vitro2013
X-ray structure determination and deuteration of nattokinase
Crystal structure at 1.74 angstrom resolution confirms nattokinase as a subtilisin-family serine protease whose three-dimensional structure is nearly identical to subtilisin E from Bacillus subtilis, differing at essentially one residue.
Journal of Synchrotron Radiation - In vitro2006
Effects of nattokinase, a pro-fibrinolytic enzyme, on red blood cell aggregation and whole blood viscosity
Confirms nattokinase is a 275-residue, 27.7 kDa subtilisin-family protease. Incubating human blood samples with nattokinase produced a dose-dependent fall in red-cell aggregation and low-shear blood viscosity, at concentrations similar to those used in prior animal trials.
Clinical Hemorheology and Microcirculation - In vitro2008
Nattokinase-promoted tissue plasminogen activator release from human cells
Heat-inactivated Bacillus subtilis natto culture and marketed nattokinase both stimulated tissue plasminogen activator (tPA) release from human vascular endothelial cells and HeLa cells, raising tPA activity up to roughly 24-fold over control, evidence for an indirect fibrinolytic mechanism beyond direct fibrin cleavage.
Pathophysiology of Haemostasis and Thrombosis - Review2017
Nattokinase: An Oral Antithrombotic Agent for the Prevention of Cardiovascular Disease
Review of proposed mechanisms (direct fibrin/fibrinogen hydrolysis, prourokinase-to-urokinase conversion, PAI-1 degradation, tPA stimulation), production methods, and safety data; notes a US Phase 2 atherothrombotic-prevention trial was underway at the time of writing.
International Journal of Molecular Sciences - Human2008
Effects of nattokinase on blood pressure: a randomized, controlled trial
Randomized, double-blind, placebo-controlled trial, 86 adults with pre-hypertension or stage 1 hypertension (73 completed), 2,000 FU/day for 8 weeks: net change versus placebo of -5.55 mmHg systolic (95% CI -10.5 to -0.57) and -2.84 mmHg diastolic (95% CI -5.33 to -0.33), with a matching fall in plasma renin activity.
Hypertension Research - Human2016
Consumption of nattokinase is associated with reduced blood pressure and von Willebrand factor, a cardiovascular risk marker: results from a randomized, double-blind, placebo-controlled, multicenter North American clinical trial
North American RCT, 79 hypertensive adults (74 completed), 100 mg/day (about 2,000 FU) of vitamin K2-depleted nattokinase (NSK-SD) for 8 weeks, sponsored by the product's US distributor: diastolic blood pressure fell from 87 to 84 mmHg versus a flat placebo group (p<0.05), with a larger drop in men (86 to 81 mmHg, p<0.006); a fall in von Willebrand factor was seen in women only at p<0.1.
Integrated Blood Pressure Control - Human2009
Nattokinase decreases plasma levels of fibrinogen, factor VII, and factor VIII in human subjects
Open-label, self-controlled trial, 45 subjects across healthy, cardiovascular-risk and dialysis groups, 4,000 FU/day for 2 months: fibrinogen fell 7 to 10%, factor VII 7 to 14%, factor VIII 17 to 19% (all p<0.001 for the time effect) across groups; no placebo or control arm, and blood lipids did not change.
Nutrition Research - Human2015
A single-dose of oral nattokinase potentiates thrombolysis and anti-coagulation profiles
Double-blind, placebo-controlled crossover RCT, 12 healthy men, single 2,000 FU dose: D-dimer and fibrin degradation products rose, factor VIII activity fell, antithrombin rose, and activated partial thromboplastin time prolonged over the following 8 hours; every change stayed inside the normal reference range.
Scientific Reports - Human2013
A pilot study on the serum pharmacokinetics of nattokinase in humans following a single, oral, daily dose
Pharmacokinetic pilot, 11 healthy adults, single 2,000 FU dose: intact nattokinase was directly measurable in serum by immunoassay, peaking around 13 hours post-dose, the first direct evidence the enzyme reaches human blood in active form after oral dosing.
Alternative Therapies in Health and Medicine - Human2017
A clinical study on the effect of nattokinase on carotid artery atherosclerosis and hyperlipidaemia
Randomized but open-label, active-controlled trial at one Sun Yat-sen University TCM outpatient clinic, 82 patients (76 completed), 6,000 FU/day nattokinase versus simvastatin 20 mg/day for 26 weeks: carotid plaque size fell 36.6% on nattokinase versus 11.5% on simvastatin (p<0.01) and carotid intima-media thickness fell in both groups. The most-cited source for nattokinase and carotid plaque, but not placebo-controlled or blinded; lipid change did not correlate with the imaging change (r=0.35, p=0.09).
Zhonghua Yi Xue Za Zhi (National Medical Journal of China) - Human2022
Effective management of atherosclerosis progress and hyperlipidemia with nattokinase: A clinical study with 1,062 participants
Retrospective, non-randomized, unblinded, uncontrolled record review across multiple China clinics (2016-2020), 10,800 FU/day for 12 months in 1,001 patients: carotid intima-media thickness fell 21.7% and plaque size fell 36%; a lower 3,600 FU/day dose in 61 patients showed no such effect. Five of ten authors were employed by Sungen Bioscience, the nattokinase manufacturer, despite the paper's stated absence of commercial interest; a later corrigendum corrected a baseline-characteristics table without changing the results.
Frontiers in Cardiovascular Medicine - Human2021
Nattokinase atherothrombotic prevention study: A randomized controlled trial
The Nattokinase Atherothrombotic Prevention Study (NAPS, NCT02080520), the only large, long, placebo-controlled Western academic RCT of nattokinase: 265 adults without cardiovascular disease, median age 65.3, 2,000 FU/day for a median of 3 years, with carotid ultrasound every 6 months. No significant difference from placebo in the rate of change of carotid intima-media thickness, carotid arterial stiffness, blood pressure, or any coagulation, fibrinolysis, inflammatory or metabolic marker measured.
Clinical Hemorheology and Microcirculation - Review2023
Nattokinase Supplementation and Cardiovascular Risk Factors: A Systematic Review and Meta-Analysis of Randomized Controlled Trials
Meta-analysis of 6 RCTs, 546 participants: nattokinase significantly lowered systolic (-3.45 mmHg) and diastolic (-2.32 mmHg) blood pressure versus placebo. Pooled lipid results ran the other way: total cholesterol was higher than placebo at both low and high total dose, HDL lower and LDL higher at low dose, and glucose slightly higher, with no significant effect on triglycerides.
Reviews in Cardiovascular Medicine - Human2009
Combined nattokinase with red yeast rice but not nattokinase alone has potent effects on blood lipids in human subjects with hyperlipidemia
RCT, 47 patients with hyperlipidemia, nattokinase alone versus nattokinase plus red yeast rice versus placebo for 6 months: the nattokinase-only arm showed no significant lipid change against placebo, while the combination arm improved triglycerides, total cholesterol, LDL-C and HDL-C from month 1. Nattokinase's own lipid contribution cannot be separated from red yeast rice's in the positive result.
Asia Pacific Journal of Clinical Nutrition - Human2024
Lipid-lowering, antihypertensive, and antithrombotic effects of nattokinase combined with red yeast rice in patients with stable coronary artery disease: a randomized, double-blinded, placebo-controlled trial
Double-blind, placebo-controlled RCT, 178 patients with stable coronary artery disease already taking statins, aspirin or beta-blockers, randomized to nattokinase (3,615 FU/day), red yeast rice, the combination, or placebo for 90 days: nattokinase alone significantly lowered LDL-C versus placebo but not total cholesterol, triglycerides or HDL-C. The combination arm improved every lipid and blood pressure measure and raised antithrombin III more than placebo.
Frontiers in Nutrition - Animal2016
Toxicological assessment of nattokinase derived from Bacillus subtilis var. natto
GLP-compliant toxicology package for NSK-SD nattokinase: non-mutagenic and non-clastogenic in vitro, no adverse effect in 28-day and 90-day rat studies up to 1,000 mg/kg/day (the highest dose tested, set as the NOAEL); a small human arm found 10 mg/kg/day well tolerated over 4 weeks.
Food and Chemical Toxicology - Human2015
Consequence of patient substitution of nattokinase for warfarin after aortic valve replacement with a mechanical prosthesis
Case report: a patient self-substituted nattokinase for warfarin after mechanical aortic valve replacement. After roughly a year without warfarin, a thrombus formed on the valve and the patient needed repeat valve replacement surgery. The authors call it the first documented case of nattokinase substituted for warfarin after valve replacement and strongly discourage that use.
Proceedings (Baylor University Medical Center) - Human2021
Nattokinase-Associated Hemoperitoneum in an Elderly Woman
Case report: a 92-year-old woman with atrial fibrillation, taking over-the-counter nattokinase and no prescribed anticoagulant or antiplatelet drug, developed spontaneous bleeding into the abdominal cavity and died. The authors warn against consumption of herbal supplements, especially nattokinase, in this kind of patient.
Cureus - Review2025
Navigating the Effects of Anti-Atherosclerotic Supplements and Acknowledging Associated Bleeding Risks
Review grouping nattokinase with omega-3s, berberine and garlic: favorable metabolic and vascular effects are reported across the class, but clinical efficacy depends on formulation and dose, and bleeding risk and drug-interaction potential apply to all of them, nattokinase included.
International Journal of Molecular Sciences - Human2026
Effects of Nattokinase on Inflammation and Cardiovascular Risk Markers in Patients With Dyslipidemia (NCT06183307)
An independent, non-industry, double-blind, placebo-controlled RCT of nattokinase in 48 hypertensive, dyslipidemic adults in Brazil, recruiting since 2024 with primary completion estimated December 2026, one of only two nattokinase trials currently recruiting worldwide.
ClinicalTrials.gov, Universidade Federal Fluminense - Review2020
Dr. Sam Robbins, Inc. dba HFL Solutions, LLC - Warning Letter
FDA objected to marketing a nattokinase-containing product as able to decrease arterial plaque buildup and help prevent a heart attack or stroke, concluding these disease claims made the dietary supplement an unapproved new drug regardless of the underlying data.
U.S. Food and Drug Administration
What users report
Self-reported experiences, not evidence. Nothing below was measured under controlled conditions, and reports like these cannot separate a real effect from placebo, from the training or diet change that accompanied it, or from what the product actually contained. They are here because knowing what people describe, including what goes wrong, is worth reading alongside the studies.
- Commercial capsules are almost universally standardized around 2,000 FU (about 100 mg of NSK-SD or an equivalent extract) per capsule, matching the dose used in most of the published blood pressure trials. A pharmacist-run survey of the Long COVID and ME/CFS community, published by PharmD Martha Eckey, found respondents commonly took more than that, in the 4,000 to 12,000 FU per day range, with 4,000 FU taken twice daily on an empty stomach described as a frequently reported 'sweet spot.'
- Outside the Long COVID community, the goals people describe are cardiovascular prevention in a general sense (better circulation, arterial health, blood pressure) and, in a smaller but vocal group, an attempt to address suspected microclots. In the Long COVID and ME/CFS survey specifically, respondents were taking it for fatigue, brain fog, and other post-viral symptoms tied to a microclot hypothesis that has not been established in controlled trials; about 60% of survey respondents reported some benefit, most within 2 weeks.
- Combining nattokinase with serrapeptase or lumbrokinase is common, and framed online as boosting fibrinolytic effect. Lumbrokinase is generally described as more potent than nattokinase and correspondingly more likely to cause an intense initial reaction; serrapeptase is more often associated with reports of nausea and headache and, per the same survey, less consistent perceived benefit than nattokinase itself.
- D-dimer is the marker people most often mention checking, on the reasoning that a rise indicates the enzyme is doing something; this maps loosely onto the actual RCT finding that a single dose raises D-dimer for several hours, though a self-checked D-dimer months into ongoing use is not the same measurement and has not been validated as a way to judge whether nattokinase is 'working.' Lp(a) and standard lipid panels come up as monitoring choices in cardiovascular-focused discussion, without any trial evidence that nattokinase moves Lp(a) specifically.
- The negatives named most consistently are no noticeable effect at all, easier bruising, and a specific, recurring worry: taking a fibrinolytic enzyme without any physician involved or any blood test to check on it, especially in older adults or anyone who does not know their own bleeding or clotting risk. That worry is echoed in the clinical literature; the one published death case involved exactly that pattern, an elderly patient taking over-the-counter nattokinase with no other blood-affecting medication and no monitoring.
- People on warfarin or other anticoagulants are the subject of the most consistent caution across product labels, pharmacist write-ups and forum discussion, for two distinct reasons that pull in opposite directions: nattokinase's own fibrinolytic action can add to warfarin's effect and raise bleeding risk, while the vitamin K2 that whole natto and some less-purified nattokinase extracts still contain can antagonize warfarin and lower it, in either case making the combination unpredictable rather than merely additive. Purified branded extracts such as NSK-SD are marketed as vitamin K2-depleted specifically to remove that second variable, but a buyer cannot verify vitamin K2 content from a label alone.
- Reddit's r/Supplements and r/Biohackers could not be retrieved for this entry (reddit.com is not accessible to the research tools used here), so nothing above is attributed to a specific Reddit post, and no quotation is reproduced from any source.
Sources: A published pharmacist-run survey of the Long COVID and ME/CFS supplement-using community (Martha Eckey, PharmD, writing on Substack), which is the only named, citable source for dosing and outcome patterns used here; the Health Canada licensed natural health product label and the Canadian NHPID ingredient entry, which supply the specific warfarin and bleeding-disorder caution language quoted in the legal status section; Memorial Sloan Kettering's integrative medicine monograph on nattokinase, which was used to cross-check the case reports and mechanism claims against a clinical secondary source; and the case-report and clinical literature cited directly elsewhere on this page. Reddit's r/Supplements and r/Biohackers, and any other Reddit community, could not be retrieved for this entry.
Frequently asked questions
Does nattokinase actually lower blood pressure?
This is the best-supported claim for nattokinase. A 2023 meta-analysis of 6 randomized, placebo-controlled trials (546 participants) found average reductions of 3.45 mmHg systolic and 2.32 mmHg diastolic versus placebo. The individual trials behind that pooled result are consistent: an 8-week Korean RCT in 86 people with pre-hypertension or stage 1 hypertension found -5.55/-2.84 mmHg at 2,000 FU/day, and a North American RCT found a similar diastolic effect, more pronounced in men. These are modest, comparable in size to what a single lifestyle change might produce, not a substitute for prescribed antihypertensive medication.
Does nattokinase reduce arterial plaque?
The evidence is real but weaker than its reputation suggests. The most-cited study randomized 82 people to nattokinase or simvastatin and found a larger drop in carotid plaque size with nattokinase over 26 weeks, but it had no placebo group and was not blinded. A larger, 1,062-patient study found similar imaging improvements, but it was retrospective and uncontrolled, and half its authors worked for the manufacturer of the nattokinase product tested. Set against both of those, the one placebo-controlled, blinded, multi-year trial ever run, in 265 healthy older adults at USC, found no effect on carotid intima-media thickness or arterial stiffness at all. No study has tested whether any imaging change translates into fewer strokes or heart attacks.
Can nattokinase be taken with warfarin, aspirin, or other blood thinners?
This should not be done without a physician involved. Nattokinase has its own fibrinolytic and mild anticoagulant action, documented in controlled human trials as elevated D-dimer, reduced factor VIII activity, and prolonged clotting time after a single dose, so combining it with warfarin, aspirin, clopidogrel or other anticoagulant or antiplatelet drugs is a plausible bleeding-risk interaction, not just a theoretical one. A published case report describes an elderly woman with atrial fibrillation who died of spontaneous internal bleeding while taking over-the-counter nattokinase alone, with no other blood-affecting drug, which shows nattokinase itself carries meaningful bleeding risk even without an added anticoagulant. Separately, a heart-valve patient who substituted nattokinase for prescribed warfarin developed a clot on the valve and needed repeat surgery, the opposite failure mode: an unsupervised switch away from a proven anticoagulant. Licensed Canadian product labels explicitly warn against use by anyone taking a blood-coagulation-affecting product and instruct stopping nattokinase 7 days before any scheduled surgery.
Does the vitamin K2 in natto interfere with warfarin?
It can, and it works in the opposite direction from nattokinase's fibrinolytic effect, which is what makes the combination genuinely unpredictable rather than simply additive. Whole natto and some less-purified nattokinase extracts retain vitamin K2, which promotes clotting-factor synthesis and can antagonize warfarin, potentially reducing its effect and raising clot risk, while nattokinase's own enzymatic activity can raise bleeding risk. Purified branded extracts such as NSK-SD are marketed as vitamin K2-depleted for exactly this reason, but a consumer generally cannot verify a product's vitamin K2 content from its label, and anyone on warfarin should treat any nattokinase product as a variable that needs a doctor's and likely a lab test's involvement, not something to self-manage.
Why is there so much human data on nattokinase compared to other supplements on this site, and why no outcome trial?
Nattokinase benefits from being cheap to dose safely and easy to test in short mechanistic studies, which is why so many small trials exist. What it lacks is the kind of trial that would settle whether it actually prevents heart attacks or strokes: a randomized trial of several thousand people followed for years, which costs hundreds of millions of dollars and is normally funded by whoever holds exclusive rights to sell the resulting product. Nattokinase comes from a centuries-old fermentation process that nobody can patent as a new composition of matter, so no company has the commercial incentive to fund that trial, and under US law a supplement seller cannot even advertise a disease-prevention claim while marketing it, which further reduces the commercial payoff. That explains the funding gap. It does not, by itself, prove the compound would pass such a trial if one were run.
What do people in health and longevity communities actually report?
A published pharmacist-run survey of the Long COVID and ME/CFS supplement-using community found people commonly taking 4,000 to 12,000 FU per day, well above the roughly 2,000 FU used in most published trials, often paired with serrapeptase or lumbrokinase, with about 60% of respondents reporting some benefit, mostly within 2 weeks, for fatigue and brain fog attributed to suspected microclots, a hypothesis that has not been tested in controlled trials. Outside that community the framing is more general cardiovascular support. The negatives that come up most are simply no effect, easier bruising, and unease about self-dosing a fibrinolytic enzyme without any physician or lab test involved, a concern the published case reports bear out directly. Reddit's r/Supplements and r/Biohackers could not be retrieved for this entry, so no community claim here is drawn from or attributed to a specific Reddit post.